UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO —55)

On February 6, 2020, the Panel transferred 12 civil action(s) to the United States District Court for the Southern District of Florida for coordinated or consolidated pretrial proceedings pursuant to

. See

(J.P.M.L. 2020). Since that time, 302 additional action(s) have been transferred to the Southern District of Florida. With the consent of that court, all such actions have been assigned to the Honorable Robin L. Rosenberg. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Southern District of Florida and assigned to Judge Rosenberg. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under

to the Southern District of Florida for the reasons stated in the order of February 6, 2020, and, with the consent of that court, assigned to the Honorable Robin L. Rosenberg. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Southern District of Florida. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

pending atthis ima, the. FOR THE PANEL: stay is lifted. Sb. CBA MULTIDISTRIGT LITIGATION John W. Nichols Clerk of the Panel

IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION MDL No. 2924

SCHEDULE CTO-55 — TAG-ALONG ACTIONS

DIST DIV. C.A.NO. CASE CAPTION

LOUISIANA EASTERN LAE 2 21-00349 Scott v. Glenmark Pharmaceuticals Limited et al MISSISSIPPI SOUTHERN

MSS 7 71-00021 Mackey v. Boehringer Ingelheim Pharmaceuticals, Inc.

NEVADA NV 2 21-0027] Cohen et al v. Boehringer Ingelheim Corporation et al PUERTO RICO PR 3 21—01080 Figueroa v. GlaxoSmithKline LLC et al WEST VIRGINIA SOUTHERN WVS 2 20—00536 Cosner v. Novartis, Inc.